anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Intimate partner violence (ipv) against women is characterized as a global epidemic in health care delivery due to its prevalence, high morbidity, and mortality. One of the first healthcare providers that victims interact with is nurses. Nurses should have sufficient knowledge and skills to fulfill their roles and responsibilities defined in the issue of ipv against women. Educational environments must provide nursing students with the opportunity to be aware of ipv against women and to manage cases. Institutions that add simulation content to their education programs have the potential to become the gold standard when preparing nursing students for case management of ipv against women. Screen-based simulations (SBSs) use available digital technology to represent patients, populations, or other healthcare encounters on a computer screen or a mobile tablet, smartphone, or other screen-based devices. Simulations using screens have advantages over mannequin-based simulations-the software is infinitely replicable, the simulation programs can be portable, they can be accessed asynchronously without a live instructor present, and the software can be distributed to many devices, and the programming can track massive amounts of usage data. The purpose of this research is to determine the effect of screen-based simulation method on nursing students' attitudes and practices about intimate partner violence against women. The intervention and control groups of the study with the pre-test, post-test randomized controlled experimental design will comprise fourth-year students attending a university's nursing faculty. Power analysis was performed to calculate the sample size and it was planned to include 63 students in the sample group. In the research, the intervention group will be trained on ipv through SBSs whereas the control group will be trained via online conference. The research outputs will be measured by Health Workers' Attitudes and Practices on Intimate Partner Violence Against Women Scale, Simulation Design Scale and Debriefing Experience Scale.
The present invention discloses small disturbance RNA of a receptor gene mIL-17RE of interleukin 17 and a coding gene and application thereof. The present invention has the purpose to provide the small disturbance RNA of the receptor gene mIL-17RE of the interleukin 17 and the coding gene thereof and the application for preparing treatment medicines used for treating diseases which are relevant to an RAS/MAPK signal path. The small disturbance RNA is one of the following double stranded RNA sequences: (1), a positive-sense strand is provided with an SEQ ID NO. 1 nucleotide sequence in a sequence list, and an antisense strand is provided with an SEQ ID NO. 2 double stranded RNA sequence in the sequence list; (2), the positive-sense strand is provided with an SEQ ID NO. 3 nucleotide sequence in the sequence list, and the antisense strand is provided with an SEQ ID NO. 4 double stranded RNA sequence in the sequence list; (3), the positive-sense strand is provided with an SEQ ID NO. 5 nucleotide sequence in the sequence list, and the antisense strand is provided with an SEQ ID NO. 6 double stranded RNA sequence in the sequence list. The present invention has large actual significance and a wide application prospect in the field of medical and biologic pharmacy.
Various surgical systems are disclosed. A surgical system can include a surgical robot and a surgical hub. The surgical robot can include a control unit in signal communication with a control console and a robotic tool. The surgical hub can include a display. The surgical hub can be in signal communication with the control unit. A facility can include a plurality of surgical hubs that communicate data from the surgical robots to a primary server. To alleviate bandwidth competition among the surgical hubs, the surgical hubs can include prioritization protocols for collecting, storing, and/or communicating data to the primary server.
Hereditary spastic paraplegia (HSP) is a group of familial diseases characterized by progressive corticospinal tract degeneration. Clinically, patients present with lower-limb spasticity and weakness. To date, more than 80 genetic HSP types have been identified. Despite advances in molecular genetics, novel HSP gene discoveries are ongoing, with a low genetic diagnostic yield. In this study, we aimed to determine pathogenic variants in a family with HSP, which was not diagnosed through conventional genetic testing. We clinically characterized a large family and conducted whole genome sequencing (WGS) analysis of four affected and three unaffected individuals in the family to identify the genetic cause of HSP. This family had autosomal dominant pure (uncomplicated) late childhood-onset HSP. The patients' symptoms accelerated between the ages of 20 and 30. Brain magnetic resonance images typically showed white matter changes, a thin corpus callosum, and cerebellar atrophy. We identified a heterozygous missense variant, KCNJ3 c.1297T>G (p.Leu433Val), through WGS and family genetic analysis, confirmed by Sanger sequencing. We suggest that the identification of KCNJ3 c.1297T>G (p.Leu433Val) constitutes the discovery of a potential novel gene responsible for HSP in this family. This is the first study to report the possible role of a KCNJ3 variant in HSP pathogenesis. Our findings further expand the phenotypic and genotypic spectrum of HSP.
Baseline MRIs will enable personalization of tDCS via current flow modeling for optimization to each participant with the goal of generating an average electric field of 0.25 V/m within their identified left dlPFC. The direct current delivered by any one electrode will not exceed 2.0 mA and the total amount of current from all electrodes will not exceed 4 mA. Each 20-minutes session will begin and end with a 60-second ramp up/down of current amplitude to maximize comfort.
Forsythia koreana Nakai is an ornamental plant widely cultivated in East Asia. The essential oil of F. koreana flowers (FEO) was extracted by hydrodistillation process and the volatile components were determined with gas chromatography coupled with mass spectrometry. The anti-inflammatory activity of FEO was investigated by using TPA-induced mouse ear inflammation model. The major components of FEO were identified as n-tetracosane (29.85%), n-heneicosane (17.45%), myristic acid (8.46%) and palmitaldehyde (6.22%). The TPA-induced mouse ear edema, water content, dermis thickness, epidermis thickness and nitric oxide production were decreased by FEO. Our findings suppose that the flower essential oil of F. koreana exerted anti-inflammatory activity, and may be used in the development of anti-inflammatory products in future.
The present invention discloses an oral liquid for treating the coronary heart disease and a preparation method thereof. The oral liquid mainly comprises bishydroxycoumarin, diosmetin, aloe-emodin, tea pigment, asiatic cudweed extract, daphnetin, baicalein, catechu extract, shikimic acid, polysaccharide sulfate, rutin, sesamin, vitamin D, nimodipine and purified water. The oral liquid also comprises the following auxiliary materials: a solubilizing agent, a preservative, a surfactant and a sweetener. According to the technical scheme of the invention, the oral liquid is capable of improving the immunity, enhancing the myocardial contractility, expanding coronary blood vessels, increasing the coronary blood flow, decreasing the myocardial oxygen consumption, improving the myocardial metabolism and promoting the cardiac function recovery. Meanwhile, the oral liquid is capable of inhibiting the recurrence of coronary heart diseases, reducing the onset of angina pectoris and myocardial infarction, delaying the development of coronary atherosclerosis lesion, and reducing the death rate caused by coronary heart diseases. The oral liquid is applicable to patients suffering from coronary heart diseases and subjected to non-operative treatments. The oral liquid is mild and stable in drug effect and has no obvious adverse effect.
The purpose of this project is to conduct a randomized, controlled trial (RCT) to determine if choice of antihypertensive medication influences changes in functional status and other cardiovascular risk factors among older persons with hypertension. Functional status, determined by measures of physical performance, is an important predictor of cardiovascular outcomes in older adults. Seniors with compromised function experience more CV events, have a higher risk of undergoing cardiac surgery and higher risk of CVD-related death than higher-functioning peers. Seniors with hypertension experience accelerated declines in function, and presently physical exercise is the primary strategy for preventing this decline. However, functional responses to exercise are highly variable and appear to be influenced by the type of antihypertensive medication(s) utilized to control blood pressure. Preliminary evidence suggests that, compared to other first-line antihypertensive agents, angiotensin converting enzyme (ACE) inhibitors enhance exercise-derived improvements in functional status among hypertensive seniors. This RCT will test this hypothesis. Sedentary men and women \> 60 years of age with functional limitations and hypertension will be recruited from two sites to participate in a longitudinal intervention study. Participants will be randomly assigned to one of three first-line antihypertensive agents: (1) the ACE inhibitor perindopril, (2) AT1 receptor antagonist losartan, or (3) the thiazide diuretic hydrochlorothiazide. Note: Participants with a documented history of hypersensitivity to ACE inhibitors will be randomized 1:1 to one of the two other study drugs. All participants will also participate in a structured aerobic exercise intervention. The primary aim is to determine if, compared to losartan and HCTZ, perindopril improves self-paced gait speed. The secondary aim is to determine the relative effect of perindopril on a) exercise capacity, b) body mass and composition, and c) circulating indices of cardiovascular risk. This study is expected to differentiate beneficial effects of three FDA-approved antihypertensive medications on an emerging cardiovascular risk factor in a clinically-relevant population. Thus the study has important implications for expeditiously influencing clinical practice guidelines in the prescription of antihypertensive drugs to millions of Americans.
The invention provides novel organophosphate compounds of formula (I), wherein X is selected from the group consisting of R-O-, R-S- and R-NH-, where R is an optionally substituted aromatic or heterocyclic group, or an optionally substituted alkyl or alkenyl group; Y is O or S; R1 is H or alkyl; and R2 is a group of the formula -(CH2)n- wherein n is an integer of from 0 to 10, or branched chain alkylene, or a group of the formula R3-O-R4 wherein R3 and R4 are both straight or branched chain alkylene, and salts and esters thereof. These compounds are structurally similar to organophosphate pesticides, but may be conjugated to antigenic macromolecules. The invention therefore also provides immunoconjugates for use in preparing antibodies or fragments thereof which are capable of binding to "parent"  organophosphate compounds and also the antibodies thus prepared. Such antibodies can be polyclonal or monoclonal with monoclonal antibodies being preferred. A method for detecting the presence of an organophosphate in a simple, and assay kits therefor are also provided, the method comprising the step of assaying the sample with an antibody or fragment thereof as provided by the invention. For such methods, the antibody can optionally be labelled or bound to a support or both. The methods of the invention are applicable to all classes of organophosphates.
Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal types of tumor amongst all human cancers due to late diagnosis and resistant to treatment with chemotherapy and radiation. Preclinical and clinical studies have revealed that ErbB family for example epidermal growth factor receptor (EGFR) is a validated molecular target for pancreatic cancer prevention and therapy. The ErbB signaling cascade is regulated by a member of the ADAM (a disintegrin and metalloprotease) family, namely ADAM17, by enzymatic cleavage of precursor ligands into soluble cytokines and growth factors. Mouse genetic studies have demonstrated that ADAM17 is required for PDAC development. In this study, we evaluated the anti-tumor effects of A9(B8) IgG—the first specific ‘human and mouse cross-reactive’ ADAM17 inhibitory antibody on pancreatic malignant transformation. We found that inhibition of ADAM17 with A9(B8) IgG efficiently suppressed the shedding of ADAM17 substrates both in vivo and in vitro. Furthermore, we demonstrated that administration of A9(B8) IgG significantly suppressed motility in human pancreatic cancer cells and also significantly delayed tumorigenesis in the Pdx1Cre;KrasG12D;Trp53fl/+ PDAC mouse model. Inhibition of ADAM17 with A9(B8) IgG particularly affected the progression of pre-invasive pancreatic lesions to advanced PDAC in mice. Taken together, the preclinical data presented here will provide a starting point for clinical applications of ADAM17 targeted therapy.
Obesity is associated with dysfunctional electrocardiographic and cardiac autonomic parameters, which may lead to increased cardiovascular morbidity. Novel electrocardiographic repolarization markers such as Tpeak-Tend (Tpe) interval have not yet been deeply studied in obese patients. We aimed to investigate the association between ventricular repolarization parameters and heart rate variability (HRV) and how they are affected by changes occurring in the cardiac autonomic nervous system. Ninety subjects categorized by Southeast Asian BMI (kg/m2) standards - normal (18-22.9), overweight (23-24.9), and obese (> 24.9), underwent assessment of ventricular repolarization parameters and HRV. Linear correlation between different parameters was also conducted. Obese subjects exhibited longer QTc and Tpe intervals compared to normal-weight subjects (p-value < 0.001, 0.026 respectively). The QTc interval showed a significant correlation (p < 0.05) with all HRV parameters by linear correlation, while the Tpe interval did not. Anthropometric parameters (BMI, WC, and WHR) were also correlated to both ventricular repolarization variables and HRV. While changes in the QTc interval may be due to obesity and/or autonomic changes occurring in the obese state, the Tpe interval does not show a relation with autonomic parameters. Thus, implicating that a change in the Tpe interval is primarily due to the direct effect of either cardiac or visceral obesity. The observed associations between ECG parameters, obesity indices, and HRV parameters suggest a role for ECG in screening for cardiovascular morbidity.
Phosphorus is a mineral found in dairy products, nuts, and meat that is essential for bone health and many other important functions inside the body's cells. The kidneys are responsible for keeping the blood levels of phosphorus normal. Healthy kidneys do this by spilling excess phosphorus into the urine. In patients with chronic kidney disease, the kidneys are unable to spill an adequate amount of phosphorus so that excess phosphorus can accumulate in the walls of blood vessels leading to heart disease, their leading cause of death. A recently discovered hormone called FGF-23 helps control the blood levels of phosphorus by "telling" the kidney how much phosphorus to spill in the urine. The purpose of this study is to learn more about how FGF-23 helps the kidneys control the blood levels of phosphorus. The ultimate goal is to use this information to design improved treatment strategies for phosphorus-related problems for the millions of patients with chronic kidney disease.
BACKGROUND: Acceptance of health care professionals is of paramount importance for the uptake and implementation of eHealth. The Unified Theory of Acceptance and Use of Technology (UTAUT) model is a widely used framework for studying health care professionals' acceptance and actual use of eHealth among general client populations. However, there is limited understanding of the eHealth acceptance of health care professionals working with people with intellectual disabilities (ID).
OBJECTIVE: This study aimed to explore the applicability of the UTAUT model toward understanding the acceptance, intention to use, and actual use of eHealth among support staff and therapists working with people with ID.
METHODS: A total of 2 cross-sectional survey studies were conducted among health care professionals from 5 health care organizations for people with ID in the Netherlands in 2018 (n=311) and in 2021 during the COVID-19 pandemic (n=326). In addition to confirmatory and exploratory factor analyses to evaluate both the original UTAUT model and an extended version, descriptive analysis was used to explore participants' characteristics, acceptance levels, and eHealth usage. Moderator analysis and multiple regression analysis were also used.
RESULTS: A confirmatory factor analysis indicated a poor fit for both the original 4-factor UTAUT model and the extended version. An exploratory factor analysis was then conducted, resulting in a more satisfactory 5-factor model after removing 1 item with a factor loading <.40. Internal consistency of the 5 factors ranged from acceptable to good (Cronbach α=.76-.85). Collectively, all factors predicted the intention to use eHealth in 2018 (R2=0.47; F5,305=54.885; P<.001) and in 2021 (R2=0.43; F5,320=49.32; P<.001). Participants scored moderately on all 5 acceptance factors in both 2018 and 2021. Moderator analysis indicated that age and voluntariness influence the relationship between factors that determined acceptance and intention to use eHealth.
CONCLUSIONS: The findings from 2 cross-sectional studies conducted in 2018 and 2021, using an extended UTAUT model, gave a deeper understanding of eHealth acceptance among health care professionals who work with people with ID.
OBJECTIVE: To examine the treatment of gender dysphoria described in Bell v Tavistock (UK 2020). Bell documents the treatment and sequelae of a 16-year-old adolescent referred to the Tavistock with gender dysphoria. Her case highlights contrasts between gender affirming care and comprehensive care.
CONCLUSIONS: Consistent with other western centres, in the 2010s, the Tavistock began treating patients with gender dysphoria under the 'Dutch protocol' for gender affirming care. Bell reveals concerning lapses of clinical governance influenced by activists and linked to patient harm. The recent suspension of a senior child psychiatrist from an Australian public hospital service after questioning the evidence base and ethical foundation of gender affirming care underlines the need to resolve these uncertainties to address the crisis in the treatment of gender dysphoria.
PURPOSE: A vaccine for preventing iridovirus using iridovirus antigenic peptides is provided to induce humoral immunity. CONSTITUTION: An iridovirus antigenic peptide has an iridovirus capsid protein in which 1st, 21th, and 427-454th amino acids are removed. The capsid protein has an amino acid of sequence number 1. An antigenic peptide has an amino acid sequence of sequence number 2. A recombinant nucleic acid encodes the iridovirus antigenic peptide. A vector contains the recombinant nucleic acid.
If subjects are eligible and decide to participate, they will take part in two identical study trials. One is scheduled before and the other is scheduled after 1 week of overeating controlled by the study team. Subjects who exercise regularly will be instructed to exercise the day before their first study trial - and they will be required to exercise during 6 of the 7 days of the overeating period (including the day before their second study trial). Subjects who do not regularly exercise (no planned physical activity) will remain inactive until the completion of both study trials.

Before each study trial If a subject is a regular exerciser, they will be asked to come to the Substrate Metabolism Laboratory in the afternoon before each of the 2 study trials to exercise in the lab for 45 min at a moderate intensity. The evening before the study trial, all subjects will need to eat a standardized dinner meal and snack. They must eat the meal and snack at specific times as indicated by the research staff. After eating the snack, subjects will need to fast (no food or beverages - besides water) overnight.

During each study trial Subjects will arrive at the Substrate Metabolism Laboratory at 7:00AM and will rest quietly for approximately 30 min. After which, the study team will measure their resting blood pressure and their resting metabolic rate. An intravenous catheter (IV) will then be placed in a vein of the subject's hand or forearm for blood sampling. The research team will then collect a small sample of fat tissue in the subject's abdomen with a needle. Next, subjects will drink a sweet sugar solution for an Oral Glucose Tolerance Test (OGTT) and the research team will collect blood samples every 15 min for 3 hours. After this 3 hour test, the IV catheter will be removed and subjects will be provided breakfast and discharged.
A range of optical interventions have been developed to slow the progression of myopia. This review summarizes key studies and their outcomes. Peer-reviewed, randomized controlled clinical trials of at least 18 months duration were identified. Randomized clinical trials were identified and summarised: 13 for spectacles, 5 for overnight orthokeratology, 5 for soft contact lenses, and 3 for orthokeratology combined with low concentration atropine. Overnight orthokeratology trials were the most consistent with 2-year slowing of axial elongation between 0.24 and 0.32 mm. Other modalities were more variable due to the wide range of optical designs. Among spectacle interventions, progressive addition lenses were the least effective, slowing axial elongation and myopia progression by no more than 0.11 mm and 0.31 D, respectively. In contrast, novel designs with peripheral lenslets slow 2-year elongation and progression by up to 0.35 mm and 0.80 D. Among soft contact lens interventions, medium add concentric bifocals slow 3-year elongation and progression by only 0.07 mm and 0.16 D, while a dual-focus design slows 3-year elongation and progression by 0.28 mm and 0.67 D. In summary, all three optical interventions have the potential to significantly slow myopia progression. Quality of vision is largely unaffected, and safety is satisfactory. Areas of uncertainty include the potential for post-treatment acceleration of progression and the benefit of adding atropine to optical interventions.
PURPOSE:To obtain a preventing and treating agent containing disophenol as an active ingredient, capable of safely, effectively and surely treating human and mammalian animal cataract and readily applicable. CONSTITUTION:The objective agent containing disophenol (2,6-diiodo-4- nitrophenol) being a medicine widely used as an excellent for tapeworm of dog as an active ingredient. When the agent is used, administration method by injection is most effective. The production of injection is carried out according to producing method of usual injection and, as necessary, pH controller, isotonic agent, buffer, etc., is added thereto. Disophenol is preferably administered subcutaneously in a dose of about 5-10mg per kg of patient and preferably injected once weekly. Furthermore, the agent is usable internally to mammalian animals.